SCHEMBL24029280

SCHEMBL24029280

CCc1nc(NC(=N)N)nc2cc(OC)ccc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.43
ALDH1A1 P00352 6/20 0.43
NPSR1 Q6W5P4 2/20 0.42
MPO P05164 1/20 0.41
RAB9A P51151 2/20 0.40
CYP2D6 P10635 1/20 0.39
DRD1 P21728 1/20 0.39
HTR2A P28223 1/20 0.39
ADORA1 P30542 1/20 0.39
MAPT P10636 5/20 0.39
GAA P10253 2/20 0.39
ADORA2A P29274 2/20 0.39
KCNH2 Q12809 1/20 0.38
GLA P06280 1/20 0.38
HPGD P15428 1/20 0.38
POLB P06746 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
HTT P42858 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26173847 0.89 NPSR1 (0.43) KDM4EALDH1A1NPSR1MPORAB9A
SCHEMBL31320223 0.83 NPSR1 (0.61) KDM4EALDH1A1NPSR1MPORAB9A
SCHEMBL2459826 0.83 NPSR1 (0.61) KDM4EALDH1A1NPSR1MPORAB9A
SCHEMBL23009236 0.83 KMT2A (0.43) KDM4EALDH1A1RAB9AADORA1MAPT
SCHEMBL6695881 0.78 MAPT (0.53) KDM4EALDH1A1NPSR1ADORA1MAPT
SCHEMBL12942514 0.75 ALDH1A1 (0.47) KDM4EALDH1A1RAB9AMAPTGAA
SCHEMBL4104105 0.75 KDM4E (0.65) KDM4EALDH1A1NPSR1RAB9AMAPT
SCHEMBL7055308 0.75 KDM4E (0.55) KDM4EALDH1A1NPSR1MPORAB9A
SCHEMBL6692482 0.72 MAPT (0.54) KDM4EALDH1A1RAB9ACYP2D6ADORA1
SCHEMBL7056204 0.70 LMNA (0.50) KDM4EALDH1A1NPSR1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230183187-A1 QUINAZOLINE COMPOUNDS AS INHIBITORS OF PREMATURE TERMINATION CODONS CENTRE NAT RECH SCIENT (FR) 2023-06-15 US disclosed
US-20230183187-A1 QUINAZOLINE COMPOUNDS AS INHIBITORS OF PREMATURE TERMINATION CODONS CENTRE NAT RECH SCIENT (FR) 2023-06-15 US disclosed
WO-2021228945-A1 QUINAZOLINE COMPOUNDS AS INHIBITORS OF PREMATURE TERMINATION CODONS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2021-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183187-A1 QUINAZOLINE COMPOUNDS AS INHIBITORS OF PREMATURE TERMINATION CODONS UPF1, NUDT21, REV1 KDM4E 2993/4885ALDH1A1 4190/4885NPSR1 3334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.